Suchergebnisse - "Lu, Jia-Cheng"

PubPharm (36)

1

Correction : Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis

enthalten in: Molecular cancer | 2024

von Huang, X. | Zhang, P. | Wei, C. | +9

ErratumFor: Mol Cancer. 2020 May 19;19(1):92. - PMID 32430013

2

Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma

enthalten in: Nature communications | 2024

von Lu, J. | Wu, L. | Sun, Y. | +27

3

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma : a single-center, single-arm, phase 2 study

enthalten in: Signal transduction and targeted therapy | 2023

von Shi, G. | Huang, X. | Wu, D. | +20

4

The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion

enthalten in: Hepatology international | 2023

von Meng, X. | Lu, J. | Zeng, H. | +19

5

Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis

enthalten in: Cell death & disease | 2023

von Guo, X. | Huang, X. | Yang, X. | +15

6

The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion

enthalten in: Hepatology international | 2022

von Meng, X. | Lu, J. | Zeng, H. | +19

7

The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion

enthalten in: Hepatology international | 2022

von Meng, X. | Lu, J. | Zeng, H. | +19

8

KSR2-14-3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma

enthalten in: Biomarker research | 2022

von Gao, C. | Wang, S. | Lu, J. | +10

9

KSR2-14–3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma

enthalten in: Biomarker Research | 2022

von Gao, C. | Wang, S. | Lu, J. | +10

10

Current applications and future perspective of CRISPR/Cas9 gene editing in cancer

enthalten in: Molecular cancer | 2022

von Wang, S. | Gao, C. | Zheng, Y. | +7